Authors

Dan Douer, MD, MKSCC

Latest:

Specialty Pharmacy: Build, Buy, or Partner

For oncology practices that want to expand specialty pharmacy services on behalf of their patients, should they build, buy, or partner?

Dan George, MD, Duke Cancer Center

Latest:

Advanced Prostate Cancer: Remaining Challenges

Experts discuss challenges and unmet needs in men with advanced prostate cancer who are undergoing treatment with androgen deprivation therapy.

Daniel J. George, MD, Duke Cancer Institute

Latest:

ASCO 2020: Updates in Prostate Cancer Treatment

Dan J. Raz, MD

Latest:

Dr. Raz on the Effects of COVID-19 on Lung Cancer Screening

Dan J. Raz, MAS, MD, discusses the effects of COVID-19 on lung cancer screening.

Dan Klein

Latest:

Payment Assistance for Patients With Cancer

Dan Klein, President and CEO of Patient Access Network Foundation, discusses payment assistance for patients with cancer.

Dan Pollyea, MD, MS, University of Colorado Cancer Center

Dan Theodorescu, MD, PhD

Latest:

Can New Technologies Be Used to Predict Treatment Response in Cancer Patients?

The next leap forward in cancer treatment will see physicians tailoring treatments based on patients' individualized tumor profiles.

Dan Zandberg, MD

Latest:

Dr. Zandberg on Biomarker Development in Head and Neck Cancer

Dan Zandberg, MD, assistant professor of medicine, the University of Maryland School of Medicine, discusses biomarker development in patients with head and neck cancer.

Dana Chase, MD

Dana Chase, MD, is an associate professor of obstetrics and gynecology in the Division of Gynecologic Oncology at UCLA Health.

Latest:

Unmet Needs and Future Research Focus for Endometrial Cancer

Panelists discuss how addressing molecular, clinical, and access-related gaps remains essential for advancing endometrial cancer research and care.

Dana Chase, MD, FACOG

Latest:

Dr. Chase on the Importance of Genetic Testing for BRCA Mutations in Ovarian Cancer

Dana Chase, MD, FACOG, gynecologic oncologist, discusses the importance of utilizing genetic testing for BRCA mutations in ovarian cancer.

Dana E. Rathkopf, MD

Dana E. Rathkopf, MD, is a genitourinary medical oncologist and chair of the Research Council at Memorial Sloan Kettering Cancer Center in New York.

Latest:

Dr Rathkopf on the Rationale for Evaluating Niraparib Plus Abiraterone Acetate in HRR+ mCSPC

Dana E. Rathkopf, MD, discusses the purpose of evaluating niraparib plus abiraterone acetate in metastatic castration-sensitive prostate cancer.

Dana H. Felthouse, MBA

Latest:

Mission Possible: Managing Specialty Pharmacy Costs and Utilization

To get the right drug in the right amount at the right time to the patient in the most cost-effective manner

Dana Jacoby

Latest:

Dana Jacoby on How a Group of Physicians Can Become a Successful Medical Group

Dana Jacoby, senior consultant, BSM Consulting, gives advice on how a group of physicians can build a strong, healthy culture when looking to form a successful medical organization.

Dana M. Chase, MD, FACOG

Latest:

Emerging ADCs in Advanced Endometrial Cancer: Anti-TROP2 and Anti-FR Agents

Panelists discuss recent data on emerging antibody-drug conjugates in advanced and recurrent endometrial cancer, including anti-TROP2 agents like sacituzumab govitecan from the TROPiCS-03 trial, datopotamab deruxtecan from TROPION-PanTumor03, and sacituzumab tirumotecan, as well as anti–folate receptor agents like luveltamab tazevibulin and rinatabart sesutecan, while offering future perspectives and closing thoughts on the evolving role of these agents in the treatment landscape for endometrial cancer.

Dana Monroe, RN, BSN

Latest:

Dana Monroe on Yervoy Side Effect Nurse Self-Education

Dana Monroe from San Francisco Oncology Associates on Yervoy Side Effects and How Oncology Nurses Can Self-Educate

Danelle James, MD, MAS

Latest:

Dr. James on Update of Ibrutinib for Chronic Lymphocytic Leukemia

Danelle James, MD, MAS, head of Oncology at Pharmacyclics, assistant adjunct professor in the Division of Hematology-Oncology at the Chronic Lymphocytic Leukemia Research Consortium, discusses the RESONATE-2 study of ibrutinib (Imbruvica) versus chlorambucil through 5 years of treatment.